|
|
|
|
|
Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma |
| FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei |
| Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China |
|
|
|
|
Abstract Objective To explore the prognostic factors of primary mediastinal large B-cell lymphoma (PMBCL) and the effects of chemoradiotherapy versus chemotherapy alone on patients’ prognosis before and after rituximab era. Methods We extracted the data of PMBCL patients diagnosed from 2001 to 2015 from SEER database. SEER Stat software was used to calculate the incidence rate. Kaplan-Meier method and Cox regression model were used to analyze the impact of various clinical variables on prognosis. Results We included 635 patients with PMBCL. Multivariate Cox regression analysis showed that age, stage and chemotherapy were independent prognostic factors. Kaplan-Meier survival analysis showed that OS of the patients receiving chemotherapy only in 2006-2015 was significantly better than that in 2001-2005 (χ 2=10.002, P=0.002). The patients who received chemoradiotherapy had better OS than those who received chemotherapy alone from 2001 to 2005. The OS and DSS of patients receiving chemoradiotherapy were not significantly different from those of chemotherapy alone from 2006 to 2015. Conclusion The application of rituximab improves the long-term survival of PMBCL patients. The prognosis of patients who received chemoradiotherapy is comparable to that of chemotherapy alone from 2006 to 2015.
|
| Keywords
Primary mediastinal large B-cell lymphoma
Radiochemotherapy
Chemotherapy
SEER database
Survival analysis
|
|
|
| Fund:National Natural Science Foundation of China Youth Fund (No. 82000204) |
|
Issue Date: 17 March 2022
|
|
[1] Mottok A, Wright G, Rosenwald A, et al. Molecular classification
of primary mediastinallarge B-cell lymphoma using routinely
available tissue specimens[J]. Blood, 2018, 132(22): 2401-2405.
[2] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision
of the World Health Organization classification of lymphoid
neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
[3] Ahmed Z, Afridi SS, Shahid Z, et al. Primary Mediastinal B-Cell
Lymphoma: A2021Updateon Genetics, Diagnosis, and Novel
Therapeutics[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(11):
e865-e875.
[4] Martelli M, Ferreri A, Di Rocco A, et al. Primary mediastinal
large B-cell lymphoma[J]. Crit Rev Oncol Hematol, 2017, 113:
318-327.
[5] Zhou H, Xu-Monette ZY, Xiao L, et al. Prognostic factors,
therapeutic approaches, and distinct immunobiologic features in
patients with primary mediastinal large B-cell lymphoma on longterm
follow-up[J]. Blood Cancer J, 2020, 10(5): 49.
[6] Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH rituximab therapy in primary mediastinal B-cell lymphoma[J]. N Engl J Med, 2013, 368(15): 1408-1416.
[7] Wilson WH, Jung SH, Porcu P, et al. A Cancer and Leukemia
Group B multi-center study of DA-EPOCH-rituximab in untreated
diffuse large B-cell lymphoma with analysis of outcome by
molecular subtype[J]. Haematologica, 2012, 97(5): 758-765.
[8] Dunleavy K, Wilson WH. Primary mediastinal B-cell lymphoma
and mediastinal gray zone lymphoma: do they require a unique
therapeutic approach?[J]. Blood, 2015, 125(1): 33-39.
[9] Goldschmidt N, Kleinstern G, Orevi M, et al. Favorable outcome
of primary mediastinallarge B-cell lymphoma patients treated
with sequential RCHOP-RICE regimen without radiotherapy[J].
Cancer Chemother Pharmacol, 2016, 77(5): 1053-1060.
[10] Bhakta N, Liu Q, Yeo F, et al. Cumulative burden of cardiovascular
morbidity in paediatric, adolescent, and young adult survivors
of Hodgkin's lymphoma: an analysis from the St Jude Lifetime
Cohort Study[J]. Lancet Oncol, 2016, 17(9): 1325-1334.
[11] Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns
and comparative effectiveness in elderly diffuse large B-cell
lymphoma patients: a surveillance, epidemiology, and end resultsmedicare
analysis[J]. Oncologist, 2014, 19(12): 1249-1257.
[12] Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel
CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J]. N
Engl J Med, 2017, 377(26): 2531-2544.
[13] Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety
and activity of axicabtagene ciloleucel in refractory large B-cell
lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2
trial[J]. Lancet Oncol, 2019, 20(1): 31-42.
[14] Vardhana S, Hamlin PA, Yang J, et al. Outcomes of Relapsed
and Refractory Primary Mediastinal (Thymic) Large B Cell
Lymphoma Treated with Second-Line Therapy and Intent to
Transplant[J]. Biol Blood Marrow Transplant, 2018, 24(10):
2133-2138.
[15] Giri S, Bhatt VR, Pathak R, et al. Role of radiation therapy in
primary mediastinal large B-cell lymphoma in rituximab era: A
US population-based analysis[J]. Am J Hematol, 2015, 90(11):
1052-1054.
[16] Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab,
cyclophosphamide,doxorubicin, vincristine, and prednisone
with or without radiotherapy in primary mediastinal large B-cell
lymphoma: the emerging standard of care[J]. Oncologist, 2012,
17(2): 239-249.
[17] Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary
mediastinal B-cell lymphoma with positron emission tomography
positivity after rituximab chemotherapy[J]. Int J Radiat Oncol
Biol Phys, 2013, 87(2): 311-316.
[18] Messmer M, Tsai HL, Varadhan R, et al. R-CHOP without
radiation in frontline management of primary mediastinal B-cell
lymphoma[J]. Leuk Lymphoma, 2019, 60(5): 1261-1265.
[19] Hayden AR, Tonseth P, Lee DG, et al. Outcome of primary
mediastinal large B-cell lymphoma using R-CHOP: impact of a
PET-adapted approach[J]. Blood, 2020, 136(24): 2803-2811.
[20] Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, et
al. Positron emission tomography after response to rituximab-
CHOP in primary mediastinal large B-cell lymphoma: impact
on outcomes and radiotherapy strategies[J]. Ann Hematol, 2021,
100(9): 2279-2292.
[21] Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in
Relapsed or Refractory Primary Mediastinal Large B-Cell
Lymphoma[J]. J Clin Oncol, 2019, 37(34): 3291-3299.
[22] Zinzani PL, Santoro A, Gritti G, et al. Nivolumab Combined
With Brentuximab Vedotin for Relapsed/Refractory Primary
Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From
the Phase Ⅱ CheckMate 436 Study[J]. J Clin Oncol, 2019,
37(33): 3081-3089.
[23] Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in
lymphoma: challenges and opportunities[J]. Ann Transl Med,
2021, 9(12): 1037.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
